Intravenous chlorimipramine and depressive subtypes.
An open clinical trial with intravenous chlorimipramine was carried out on twenty depressed inpatients, diagnosed as primary or secondary affective disorders following a classificatory scheme for use in psychiatric research. Eleven of twelve patients with primary affective disorders had a significant decrease in symptoms of depression at the end of two weeks. In contrast, eight patients with secondary affective disorders did not show such significant improvement. Changes in physiological parameters (systolic blood pressure) were significantly greater in the primary affective disorders than in the secondary ones. It is inferred from the results of this trial, that intravenous administration of chlorimipramine is a safe and feasible procedure, which may compare to electroconvulsive therapy in the treatment of severe unipolar and bipolar depressions.
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002997:Clomipramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000145:classification / Q000188:drug therapy*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
D003984:Dibenzazepines; D002997:Clomipramine